3.34 0.07 (2.14%) | 02-14 16:00 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 4.42 | 1-year : | 4.95 |
Resists | First : | 3.78 | Second : | 4.23 |
Pivot price | 3.52 ![]() |
|||
Supports | First : | 3.05 | Second : | 2.54 |
MAs | MA(5) : | 3.27 ![]() |
MA(20) : | 3.52 |
MA(100) : | 5.65 ![]() |
MA(250) : | 7.23 ![]() |
|
MACD | MACD : | -0.3 ![]() |
Signal : | -0.3 ![]() |
%K %D | K(14,3) : | 18.6 ![]() |
D(3) : | 12.2 ![]() |
RSI | RSI(14): 40.6 ![]() |
|||
52-week | High : | 13.06 | Low : | 3 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ LRMR ] has closed above bottom band by 29.8%. Bollinger Bands are 53.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 27 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 3.47 - 3.48 | 3.48 - 3.49 |
Low: | 3.27 - 3.28 | 3.28 - 3.3 |
Close: | 3.32 - 3.34 | 3.34 - 3.37 |
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Wed, 12 Feb 2025
Insiders Re-Evaluate Their US$522.0k Stock Purchase As Larimar Therapeutics Falls To US$215m - Simply Wall St
Tue, 04 Feb 2025
Analysts Set Larimar Therapeutics, Inc. (NASDAQ:LRMR) PT at $20.13 - MarketBeat
Wed, 29 Jan 2025
Truist Initiates Larimar Therapeutics at Buy With $18 Price Target -January 29, 2025 at 06:37 am EST - Marketscreener.com
Wed, 29 Jan 2025
Truist Securities Initiates Coverage of Larimar Therapeutics (LRMR) with Buy Recommendation - Nasdaq
Thu, 23 Jan 2025
Larimar Therapeutics Announces Dosing of Adolescents in - GlobeNewswire
Wed, 08 Jan 2025
JANUS HENDERSON GROUP PLC Acquires Additional Shares in Larimar Therapeutics Inc - GuruFocus.com
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 64 (M) |
Shares Float | 32 (M) |
Held by Insiders | 1.7 (%) |
Held by Institutions | 108 (%) |
Shares Short | 5,240 (K) |
Shares Short P.Month | 4,470 (K) |
EPS | -1.15 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 3.1 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -28.6 % |
Return on Equity (ttm) | -44.5 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -1.16 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -58 (M) |
Levered Free Cash Flow | -35 (M) |
PE Ratio | -2.91 |
PEG Ratio | 0 |
Price to Book value | 1.07 |
Price to Sales | 0 |
Price to Cash Flow | -3.66 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |